The European Medicines Agency (EMA) has started a review into the screening of patients before they begin treatment with certain drugs. Most of the drugs in question are chemotherapies, and they ...
The clinical description of severe toxicity fails to capture the suffering, shock, and tragedy experienced by our loved ones who were fatally overdosed after not being offered this important and ...
Some cancer patients react very badly to commonly used chemotherapies — but there is a test that can identify those patients. So why isn't this test being used? This is the question currently being ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it. The Food and Drug Administration (FDA) has updated ...
Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency. According to an update from the Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results